Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Bariatric Surgery in Children. (BASIC)

25 de agosto de 2021 actualizado por: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Limburg
      • Maastricht, Limburg, Países Bajos, 6202ZA
        • Maastricht University Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

14 años a 16 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Grupo de control
Control group will receive standard therapy consisting of combined lifestyle interventions.
Experimental: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Weight
Periodo de tiempo: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Periodo de tiempo: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Periodo de tiempo: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Periodo de tiempo: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Body composition
Periodo de tiempo: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Periodo de tiempo: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Periodo de tiempo: 6 months
6 months
Inflammatory status
Periodo de tiempo: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Periodo de tiempo: 6 months
6 months
Non-alcoholic fatty liver disease
Periodo de tiempo: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Periodo de tiempo: 6 months
6 months
Behaviour changes
Periodo de tiempo: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Periodo de tiempo: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Periodo de tiempo: 6 months
6 months
Brain development
Periodo de tiempo: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Periodo de tiempo: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Periodo de tiempo: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Periodo de tiempo: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Periodo de tiempo: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Periodo de tiempo: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Periodo de tiempo: 12 months
12 months
Metabolic and endocrine changes
Periodo de tiempo: 24 months
24 months
Metabolic and endocrine changes
Periodo de tiempo: 36 months
36 months
Inflammatory status
Periodo de tiempo: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Periodo de tiempo: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Periodo de tiempo: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Periodo de tiempo: 12 months
12 months
Cardiovascular abnormalities
Periodo de tiempo: 24 months
24 months
Cardiovascular abnormalities
Periodo de tiempo: 36 months
36 months
Non-alcoholic fatty liver disease
Periodo de tiempo: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Periodo de tiempo: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Periodo de tiempo: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Periodo de tiempo: 12 months
12 months
Quality of life changes
Periodo de tiempo: 24 months
24 months
Quality of life changes
Periodo de tiempo: 36 months
36 months
Effects on sleep architecture
Periodo de tiempo: 12 months
12 months
Effects on sleep architecture
Periodo de tiempo: 24 months
24 months
Effects on sleep architecture
Periodo de tiempo: 36 months
36 months
Behaviour changes
Periodo de tiempo: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Periodo de tiempo: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Periodo de tiempo: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Periodo de tiempo: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Periodo de tiempo: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Periodo de tiempo: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Periodo de tiempo: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Periodo de tiempo: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Periodo de tiempo: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Periodo de tiempo: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Periodo de tiempo: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Periodo de tiempo: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Periodo de tiempo: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Periodo de tiempo: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: LWE van Heurn, Professor, Maastricht University Medical Center
  • Investigador principal: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Investigador principal: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de diciembre de 2011

Finalización primaria (Anticipado)

1 de diciembre de 2022

Finalización del estudio (Anticipado)

1 de diciembre de 2022

Fechas de registro del estudio

Enviado por primera vez

22 de julio de 2010

Primero enviado que cumplió con los criterios de control de calidad

29 de julio de 2010

Publicado por primera vez (Estimar)

30 de julio de 2010

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

26 de agosto de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

25 de agosto de 2021

Última verificación

1 de agosto de 2021

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NL26279.068.09

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir